Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly and Company is conducting a study titled ‘A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk.’ The study aims to evaluate the safety and efficacy of the oral drug orforglipron against insulin glargine in individuals with type 2 diabetes who are also obese or overweight and at increased cardiovascular risk.
The study tests two interventions: orforglipron, an experimental oral drug taken once daily, and insulin glargine, an active comparator administered subcutaneously. Orforglipron is designed to offer a convenient oral alternative to traditional insulin therapy.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. It involves approximately 27 visits over two years, assessing the comparative effectiveness of the two treatments.
The study began on April 3, 2023, with an estimated primary completion date in 2025. The last update was submitted on July 1, 2025, indicating ongoing progress and data collection.
The outcome of this study could significantly impact Eli Lilly’s stock performance, as a successful result may enhance their market position in diabetes treatment. Investors should watch for updates, as positive findings could shift market dynamics, especially against competitors in the diabetes care industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.